The ability to predict TDP-43 and tau pathology using neuroimaging is crucial, as it is likely these proteinopathies require therapeutics with distinct mechanisms of action, thus allowing for precision medicine approaches such as pathology-based treatment. The gene discussed is TARDBP; the disease is proteostasis deficiencies.